DongKook Life Science Co Ltd

DongKook Life Science has a market price of 3,300 KRW and a market cap of 105.55 billion KRW, with a price-to-earnings ratio of 12.19 and a price-to-book ratio of 0.8. The company's liquidity position is characterized by a current ratio of 1.72, but its cash and equivalents of 1.96 billion KRW are significantly lower than its long-term debt of 38.98 billion KRW, resulting in a negative net cash position. The debt-to-equity ratio of 0.3 suggests a relatively conservative capital structure. Profitability metrics show a return on equity (ROE) of 6.59% and a return on assets (ROA) of 3.98%, both below the typical thresholds for high-performing pharmaceutical firms. The company's operating income of 13.05 billion KRW and net income of 8.66 billion KRW indicate a healthy margin, but the gross profit of 32.99 billion KRW suggests room for improvement in cost management. The company's revenue is concentrated in its core business of contrast agents and medical equipment distribution, with no disclosed geographic diversification. This lack of geographic segmentation increases exposure to regional economic and regulatory risks. The company's free cash flow of 10.19 billion KRW and operating cash flow of 433.65 million KRW support its operations but are insufficient to cover capital expenditures of -5.69 billion KRW. Looking ahead, the company's revenue is expected to grow, supported by its strong position in the contrast agents market. However, the capital expenditure of -5.69 billion KRW indicates ongoing investment in infrastructure or expansion. The company's liquidity risk is moderate, with a current ratio of 1.72, but the negative net cash position raises concerns about short-term solvency. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's key financial flag is the negative net cash position after subtracting total debt, which could impact its ability to fund operations without external financing. The dilution risk is low, with no significant changes in shares outstanding between basic and diluted shares. Recent financial filings and transcripts indicate stable operations, with the last actual EPS at 275.00 KRW and revenue at 130.34 billion KRW. These figures align with the company's historical performance and suggest a consistent earnings profile.